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Abstract
Background: Hepatitis B virus (HBV) and hepatitis D virus (HDV) represent important public health problems in
the Western Amazon region with reported cases of fulminant hepatitis. This cross sectional study describes HBV
and HDV genotypes circulating in the Brazilian Amazon region.
Methods: HBsAg positive individuals (n = 224) were recruited in Manaus/Amazonas State (130 blood donors from
the Hematology and Hemotherapy Foundation from Amazonas/HEMOAM; 60 subjects from outpatient clinic) and
in Eirunepe city (n = 34) from 2003–2009. Most participants (n = 153) lived in Manaus, 63 were from 20 remote
isolated municipalities, 8 lived outside Amazonas State. Genotyping was based on PCR products: HBV genotype
A-F specific primers, restricted length polymorphism for HDV. HDV isolates were directly sequenced (delta antigen
405 nucleotide fragment) and phylogenetic analysis performed (MEGA; neighbor-joining, Kimura’s two parameter).
Results: Most participants were young adult males and HBV mono-infection predominated (70.5%, 158/224).
Among blood donors, outpatient subjects and individuals from Eirunepe, HBV/A prevailed followed by HBV/D and
F (p > 0.05). HBV/A was more frequent in blood donors (p < 0.05). HBV-HDV coinfection rate was 8.5% in blood
donors (11/130), 65.0% (39/60) in outpatient subjects and 47.0% (16/34) in individuals from Eirunepe. Compared to
blood donors, coinfection was higher in outpatient subjects (65.0% versus 8.5%; RR = 5.0; CI 3.4-7.9; p < 0.0001) and
in subjects from Eirunepe (47.0% versus 8.5%; RR = 5.5; CI 3.0-9.9; p < 0.0001). HBV-HDV coinfection rates were higher
in patients from highly endemic remote cities. Only HDV genotype 3 was detected, HBV/F-HDV/3 predominated
(20/38; 52.7%), followed by HBV/A-HDV/3 (31.6%; 12/38) and HBV/D-HDV/3 (15.8%; 6/38).
Conclusions: The description of HBV and HDV genotypes circulating in the western Amazon can contribute to a
better understanding of their relevance on the regional epidemics. These infections are highly endemic in the
Amazon where their control is challenged by its vast territorial dimension with small, hard-to-reach municipalities
dispersed into the jungle and populated by diverse ethnic groups.
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Background
Worldwide more than 350 million subjects have chronic
infection with hepatitis B virus (HBV) and around 15–20
million people are coinfected with hepatitis D virus (HDV)
[1]. HDV is a defective RNA virus that requires the hepa-
titis B surface antigen (HBsAg) to become infectious [2].
HBV and HDV share similar transmission routes, primarily
parenteral and sexual routes, but in areas of high en-
demicity as the Amazon basin, vertical and childhood
horizontal transmission of HBV also occurs [3,4]. Several
reports have shown that chronic HDV-HBV coinfection is
associated with more severe liver disease than chronic HBV
monoinfection [5,6]. HDV can be acquired by coinfection
with HBV or by superinfection of HBV carrier and the clin-
ical outcome of HDV depends on the modality of infection.
Coinfection leads mostly to clearance of HBV-HDV in 95%
of patients, whereas superinfection results in chronic
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infection in over 90% of the patients [7]. HDV is a highly
pathogenic virus but the range of clinical manifestations
vary from mild disease to fulminant hepatitis, as well as a
rapidly progressive form of chronic viral hepatitis [8].
Delta hepatitis was endemic in southern Europe where
between 1980–1990 the prevalence of anti-HDV anti-
bodies among HBsAg-positive individuals was higher
than 20%. Following the implementation of HBV vaccin-
ation programs in the 1990s a significant decline in inci-
dence was reported [9]. However, incidence is increasing
in northern and central Europe because of immigration
from highly endemic areas and intravenous drug use. In
the Mediterranean region, in Africa, and in the Middle
East, high rates of HBsAg carriers can be coinfected with
HDV whereas in the USA, HDV remains rare and re-
stricted to high-risk groups such as intravenous drug users
and hemophiliacs [10,11]. Currently eight different HDV
genotypes have been reported and HDV genotype 3 is char-
acteristic of the Amazon region in South America [12-14].
The western Amazon basin (including Brazil, Peru,
Ecuador, Venezuela and Colombia) presents one of the
highest rates of HBV infection in the world [15-17].
HBV is a DNA virus of high genetic variability compris-
ing eight well-recognized genotypes, A-H and two new
proposed genotypes, I and J that show distinct geo-
graphic distribution [15,18,19]. HBV genotypes together
with viral load and specific viral mutations play a role in
disease progression and in particular, HBV genotype can
be predictive of clinical outcomes and response to inter-
feron treatment [20]. HBV genotype A prevails in Brazil
followed by genotypes D and F, the later one, prevalent
in indigenous communities [21,22].
The Brazilian Amazon mainly the Juruá, the Solimões,
and the Purus river basins in the State of Amazonas are
considered highly endemic regions for HBV and HDV
where they represent important public health issues with
severe cases of acute and chronic HDV hepatitis [23-26].
Molecular epidemiology studies in this geographic region
of continental dimension, including remote and hard-to-
reach villages dispersed into the jungle, diverse population
composed by different ethnic groups and low demo-
graphic density can help delineate improved control mea-
sures for HBV-HDV coinfection. In this context, this study
describes HBV and HDV genotypes circulating in the
Western Amazon region in Brazil and these data contrib-
ute to compose the molecular epidemiology map of these
viruses indicating their pattern of endemicity in this highly
endemic area.
Methods
Study area and subjects
This cross sectional study included individuals with con-
firmed diagnosis of HBV infection, most of them living in
the western Amazon. Individuals were recruited in two
cities (Manaus and Eirunepe) located in the Amazonas
State, North Brazil from 2003–2009.
In Manaus city, two different groups of HBsAg positive
participants were included and evaluated separately: A.
Blood donors, asymptomatic subjects recruited at the main
public health reference blood bank in the north Brazilian
region “Hematology and Hemotherapy Foundation from
Amazonas”/HEMOAM (n = 130); B. Symptomatic subjects
recruited at an outpatient clinic (“Araujo Lima Hepatitis
Ambulatory Hospital, Federal University of Amazonas”;
n = 60). Manaus (the capital of Amazonas State) is the
largest city in the Amazon region and is located in
the center of the Brazilian Amazon rainforest (great
metropolitan area with around 2.2 million inhabitants, sit-
uated by the Negro River a few miles before it meets the
Solimões River to form the Amazon River). Manaus was
historically populated by several local indigenous tribes
(mainly “Manaós”) and by Portuguese and Spanish immi-
grants (16th century).
In Eirunepe city, HBV infected subjects were identified
after a serological screening for HBsAg positivity among
720 individuals performed in 2009 (34/720; 4.72% preva-
lence of HBsAg positivity, Kiesslich D unpublished data).
Eirunepe city (30665 inhabitants) is located 1160 kilometers
away from Manaus, in the southwest part of Amazonas
State by the Juruá Valley and is considered a highly
endemic region for HBV and HDV infections [27,28].
Eirunepe represents a rather isolated municipality that can
be reached only by the Juruá River and by airplane. It was
populated during the Rubber Cycle (19th century) result-
ing from the miscegenation of indigenous people (Kulinaã
tribe), Brazilians from the northeast region, Turkish,
Portuguese and Spanish immigrants. No indigenous par-
ticipant was included in any of the study groups.
Participants
Individuals from both genders, ≥18 years old, with positive
HBsAg serology (Murex, Abbot, USA) were included.
Serological marker for HDV infection was determined by
anti-HD IgG ELISA kit (DiaSorin, Saluggia, Italy). Anti
HBV-HDV coinfection was defined by HBsAg positivity
and anti-HD positivity. Exclusion criteria were: coinfection
with hepatitis C virus (MUREX/Abbot, EUA), or human T
cell lymphotropic virus (MUREX/Abbot, EUA), or human
immunodeficiency virus (MUREX/Abbot, EUA); patients
under interferon or antiviral medication, chronic alcohol
consumption and illegal drug use.
HBV genotyping
DNA was extracted from serum using silica-membrane-
based nucleic acid purification kit (QIAmp DNA, Qiagen,
Germany) and amplified by nested PCR. The first PCR
round included primers for the complete HBV surface and
in the second round, primers specific for genotypes A, B,
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C, D, E, F were included, as previously described [29].
HBV genotypes were identified in PCR products analyzed
in 1.5% agarose gel electrophoresis.
HDV genotyping
RNA was extracted from serum using silica-membrane-
based nucleic acid purification kit (QIAmp viral RNA,
Qiagen, Germany), RNA was reverse transcribed (Super-
script TM One step RT PCR Platinum Taq; Invitrogen,
Germany) and specific primers for nucleotide (nt) 883–
906 and 1288–1265 positions of HDV genome were
used [30]. For restriction fragment length polymorphism
(RFLP) the amplification products were detected in 1.5%
agarose gel and digested with restriction enzyme SmaI
(5 U) (Life Technologies). Digested products were analyzed
by electrophoresis through 6% acrylamide gels according
to the size of the fragments: genotype 1 (227-178 bp),
genotype 2 (no digestion), genotype 3 (298-107 bp) [30].
HDV sequencing and Phylogenetic Analysis
For a subset of HBV-HDV coinfected patients, HDV iso-
lates were submitted to direct sequencing of the partial
delta antigen genomic region (405 nucleotide fragment
within nucleotide positions 883–1288) using internal
primers (Big Dye terminator DNA sequencing kit, Applied
Biosystems, Foster City, CA) [30]. The sequences were
edited manually (BioEdit V.5.0.9) and alignment, phylo-
genetic and molecular analyses were performed using
MEGA version 4 with neighbor-joining method under
Kimura’s two parameter. A bootstrap test and reconstruc-
tion was done 1000 times to confirm the reliability of
the phylogenetic tree. HDV sequences from this study
were deposited at the GenBank under accession numbers:
KF278974 to KF278994.
Statistical analyses
Proportions of genders, different HBV genotypes and
HDV infections among groups of participants were com-
pared by chi square and Fisher’s exact test. Comparisons
of ages among groups employed ANOVA and Student’s
t test. Results yielding p < 0.05 were considered statisti-
cally significant.
Ethics statement
This study was approved by Institutional Review Boards
(“Comite de Etica em Pesquisa da Universidade Federal
do Amazonas/UFAM” and “Fundação de Hematologia do
Estado de Amazonas/HEMOAM”) and all participants
provided signed informed consents.
Results
Main features of participants
This molecular study included a total of 224 HBsAg
positive individuals from the Brazilian western Amazon
that were analyzed according to the recruitment site: A.
Blood donors (n = 130); B. Outpatient subjects (n = 60);
C. Subjects from Eirunepe (n = 34). In this study group
(Table 1) males predominated among blood donors and
outpatient subjects while females prevailed among par-
ticipants from Eirunepe (p < 0.0001). Outpatient subjects
were older than blood donors and than subjects from
Eirunepe (p < 0.0007). The majority of patients (153/224;
68.30%) lived in Manaus while 63 individuals lived in 20
different remote municipalities located in the interior of
the Amazonas State. Four individuals were from Lábrea, a
highly endemic region for both infections. Additionally, 8
patients lived outside Amazonas State: three were from
Boa Vista city capital, of Roraima State; one was from
Tarauacá city, one from Sena Madureira, Acre State; two
participants came from Itaituba and Tucurui, gold mining
cities in Para State and one participant was from Patu city,
Rio Grande do Norte State, northeast Brazil.
HBV infection and HBV genotypes
Overall among 224 HBsAg positive cases included in
this study, 85.26% (191/224) were genotyped for HBV:
84.61% (110/130) of blood donors, 86.66% (52/60) of
Table 1 Main demographic features, HBV genotypes in Western Amazon, Brazil
Study group Manaus Eirunepe Total
Blood donors Outpatients
Number (n) 130 60 34 224
Male: female# 98:32 38:22 12:22 -
Age# media, range 35 (18–60) 40 (19–66) 33 (18–50) -
Genotyped HBV samples (n) 110 52 29 191
% HBV A (n/total)* 61.8 (68/110) 44.2 (23/52) 48.3 (14/29) 105
% HBV D (n/total)* 15.4 (17/110) 21.1 (11/52) 17.2 (5/29) 33
% HBV F (n/total)* 22.8 (25/110) 34.6 (18/52) 34.5 (10/29) 53
*p > 0.05 for Chi square comparisons of HBV genotypes among Manaus blood donors, Manaus outpatients and Eirunepe individuals; **p < 0.05 for Fisher’s exact
test comparison of HBV A frequencies between Manaus blood donors and outpatients; #p < 0.001 for ANOVA comparisons of ages and Chi square comparison of
male:female ratios among Manaus blood donors, Manaus outpatients and Eirunepe individuals.
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individuals from outpatient clinic in Manaus and 85.29%
(29/34) of participants from Eirunepe.
HBV genotypes A, D and F were detected in all three
groups: blood donors, subjects recruited in Manaus and
in Eirunepe. The frequency of HBV genotypes identified
among outpatient subjects and among participants from
Eirunepe was similar (p > 0.05); therefore comparisons
were performed between blood donors versus subjects
from Manaus and versus subjects from Eirunepe. In
these analyses, the only significant difference in HBV
genotype distribution was the higher frequency of HBV/
A among blood donors compared to outpatient subjects
(p <0.05).
HBV-HDV coinfection and genotypes
In this study, the majority of participants (70.5%, 158/
224) had HBV mono-infection whereas around one third
were HBV-HDV coinfected (Table 2). Compared to blood
donors, HBV-HDV coinfection was more frequent among
subjects from outpatient clinic (65.0% versus 8.5%;
RR = 5.0; CI 3.4-7.9; p < 0.0001) and among participants
from Eirunepe (47.0% versus 8.5%; RR = 5.5; CI 3.0-9.9;
p < 0.0001).
Among 66 HBV-HDV coinfected individuals, 52 had
HBV genotyped and 38 had both HBV and HDV genotyped
(Table 2). HDV genotype 3 was identified in all coinfected
patients recruited in the western Amazon region. HBV/F-
HDV/3 predominated (20/38; 52.7%), followed by HBV/A-
HDV/3 (31.6%; 12/38) and HBV/D-HDV/3 (15.8%; 6/38).
The frequency of HDV/3 coinfection among blood donors
was lower (RR = 0.53; CI 0.24-1.11; p = 0.054). HDV/3
coinfection was not significantly associated with HBV
genotypes A or F. The relative risk of HDV/3 coinfection
among outpatient subjects harboring HBV/D was border-
line (RR = 0.51; CI 0.22-1.5; p = 0.07).
HDV phylogenetic analysis
The phylogenetic analysis of 21 isolates showed that HDV
genotype 3 sequences circulating in the western Amazon
in Brazil are intermixed with sequences from other
western Amazon countries as Venezuela, Colombia and
Peru (Figure 1). Four HDV/3 sequences of patients coming
from Lábrea region were intermixed with other geno-
type 3 sequences from Venezuela, Peru and other Brazilian
sequences (GenBank accession numbers KF278983,
KF278984, KF278988 and KF278993).
In Eirunepe, HDV genotype 3 sequences (KF278985
and KF278996) with high bootstrap were identified in
individuals that did not have any clear epidemiological
link, indicating a small local transmission cluster in the
Juruá Valley. HDV/3 sequences from individuals living
in several remote, isolated cities located in Purús, Negro
and Amazonas basins indicate that this genotype is widely
dispersed throughout the Amazonas State.
Discussion
This molecular epidemiology study describes HBV and
HDV genotypes circulating in the Brazilian western
Amazon including Manaus city, the capital and largest
metropolitan area of Amazonas State and several small,
remote municipalities dispersed into the Amazon jungle.
Blood donors from Manaus, outpatient subjects from sev-
eral interior cities and subjects from Eirunepe city, located
by the Juruá Valley, a highly endemic area were investi-
gated. In this study, HBV monoinfection with genotype A
predominated and genotypes D and F were also detected.
HDV genotype 3 was the only genotype identified. HBV
genotypes A, D and F and HDV/3 cases identified in sub-
jects from the western Amazon depicted in Figure 2 con-
firm the wide distribution of these variants within this
highly endemic area. In particular, HDV/3, which seems
to be unique to the Amazon basin, is indeed disseminated
throughout the area. Since HBV genotypes are known to
impact clinical outcomes, surveillance studies remain im-
portant to identify prevailing genotypes and the possible
introduction of new ones.
Brazil and Colombia were the first Latin American
countries to introduce universal vaccination against HBV.
In the western Amazon region, a widespread vaccination
program was implemented in 1999, however, HBV and
HDV infections currently remain important public health
problems given the high burden reported by public health
services. Additionally, the effect of HBV vaccination on
mortality is not clear [31]. Even under universal HBV
vaccination programs, surveillance in western Amazon
should be continued to help delineate improved measures
to control these infections and molecular epidemiology
studies are important to define the regional pattern of en-
demicity. The importance of surveillance studies can be
highlighted by the recent reports of high rates of HBV and
HDV coinfection in developed countries mainly due to the
immigration of patients from highly endemic regions
and to the increased intravenous drug use [32-34]. The
Table 2 HDV-HBV co-infection and genotypes in the
Western Amazon, Brazil
Study group Manaus Eirunepe Total
Blood donors Outpatients
Participants (n) 130 60 34 224
HBV HDV
coinfection %
8.5 (11/130) 65.0 (39/60) 47.0 (16/34) 66
Genotyped HBV
samples (n)
8/11 33/39 11/16 52/66*
HBV/A HDV/3 1 9 2 12
HBV/D HDV/3 3 3 - 6
HBV/F HDV/3 2 13 5 20
*Among 66 HBV-HDV co-infected individuals, 52 had HBV genotyped and 38 had
both HBV and HDV genotyped.
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Figure 1 Phylogenetic analysis of 21 HDV genotype 3 isolates from the western Amazon. A 405 nt fragment of delta antigen (nucleotide
positions 883–1288) was directly sequenced. Sequences from the western Amazon identified in this study are highlighted (●). Corresponding 405
nucleotide sub-genomic fragment of reference sequences were used in this analysis. For the reference sequences used, genotypes, origin and
GenBank accession numbers of are indicated.
Crispim et al. BMC Infectious Diseases 2014, 14:94 Page 5 of 9
http://www.biomedcentral.com/1471-2334/14/94
Amazon region attracts a significant number of migrants
and tourists from all over the world and should be moni-
tored regarding the possible introduction of different HBV
and HDV genotypes that circulate in other countries,
as well as their potential impact on clinical outcomes of
coinfection regionally.
In this study, HBV genotypes A, D and F were identi-
fied and genotype A predominated among blood donors
recruited in Manaus city. Our data corroborate previous
reports showing that HBV genotype A prevails in Brazil
including the northern region, followed by genotypes D
and F [21,35-40]. In general, these studies have shown
that about half of HBV circulating in Brazil is genotype
A, probably introduced from Africa by slave trade, and
in the north region, European and Lebanese immigrants
have also played a role in genotype A introduction. Im-
plications of genotype A in HBV therapy and disease
progression have been well reported. Patients infected
with HBV genotypes A and B have better responses to
interferon-based therapy than patients infected with
genotypes C and D. The predominance of HBV genotype
A in the Brazilian western Amazon region, especially in
Manaus, indicates that the majority of these individuals
may benefit from interferon therapy.
Some molecular epidemiology studies from the Brazilian
Amazon have also shown the circulation of HBV genotype
F [38-40]. In the Amazon, HBV/F has been described in
isolated tribes that did not have contact with non-indigen-
ous population, whereas among tribes that had contact
with non-indigenous populations, genotypes A and D
have been introduced [22,41]. In our study, no indigenous
participant was included and genotype F predominated
among subjects recruited in an outpatient clinic that came
from interior cities indicating that genotype F circulates
beyond indigenous populations.
HDV/3 is considered the most divergent genotype and
previous studies indicate that it is common in the Amazon
Basin although genotype 1 has also been described in this
region [42]. Results from the current study indicate wide
dissemination and predominance of HDV genotype 3 in
coinfected individuals from the western Amazon. As
expected, the phylogenetic analyses showed that the HDV
genotype 3 sequences from this study were intermixed
with sequences from other western Amazon countries
such as Colombia, Peru and Venezuela. Four HBV-HDV
coinfected patients came from the highly endemic Lábrea
region where a severe hepatitis outbreak caused by HDV,
known as Lábrea hepatitis or black fever was reported
[23]. In the current study, most coinfected patients that
were genotyped harbored HBV/F-HDV/3 combination as
previously reported [14], however, HBV/A-HDV/3 and
HBV/D-HDV/3 coinfections were also detected. In Europe,
Figure 2 South America map highlighting the Brazilian western Amazon region and HBV and HDV genotypes identified in Amazonas,
Acre and Roraima States according to the origin of the participants, indicated by a red star. HDV genotype 3 refers to the 21 isolates
sequenced and shown in Figure 1. HBV genotypes are depicted in black and HDV genotype in red. Genotypes are shown according to the origin
of participants within subregions of Amazonas State (“Alto Solimões, Jutaí/Solimões/Juruá, Purús, Juruá, Madeira, Alto Rio Negro, Rio Negro/
Solimões, Médio Amazonas”). The major hydrographic basins and from the western Amazon are shown including the Negro River/Manaus,
Juruá River/Eirunepe and Purús River/ Lábrea. (*) indicates genotypes in other Brazilian states in the north region: Pará, Roraima and Acre.
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most HBV-HDV coinfected patients harbor HBV genotype
D but infection with genotype A can also occur [43]. Our
study corroborates the diversity of HBV genotypes in HDV
coinfection.
One interesting molecular finding was that the major-
ity of HBV/F-HDV/3 cases from the current study was
detected among subjects recruited in an outpatient clinic
in Manaus. The severity of HDV infection seems to be
influenced by the HDV genotypes and HDV/3 has been
associated with higher pathogenicity, generally fulminant
hepatitis [12,44]. In South America HBV/F-HDV/3 co-
infection has been associated with increased severity of
the disease. Although out of the scope of the present
study, the identification of higher frequency of HBV/F-
HDV/3 genotypes among symptomatic patients with
liver disease seeking medical care in an outpatient clinic,
confirms the poorer clinical outcomes determined by
these genotypes. A previous study from our group in
the same geographic region, suggested a role for HBV
genotype in disease progression in which more severe
liver inflammation was seen in HDV/3-HBV/F coin-
fected patients compared to patients mono infected
with HBV/F [45]. The combination of HBV/F-HDV/3
is highly, if not invariably pathogenic, however in the
current study HBV/F-HDV/3 coinfection was also detec-
ted in a low proportion of healthy blood donors. This
finding indicates that this association is not "per se" patho-
genic, although for unexplained reasons, the risk of liver
disease in patients with this viral combination is indeed
increased.
In this study, the frequency of HDV coinfection was
lower in blood donors from Manaus and the higher rate
of coinfection detected in Eirunepe city, probably reflects
the high endemicity for these viruses already described in
this region located by the Juruá Valley. PCR amplification
rates and identification of HBV genotypes in this study
was around 85% and around 79% for HDV. This amplifi-
cation rate for HBV can be considered high, since HDV
coinfection spontaneously suppresses HBV, limiting amp-
lification rates and analysis of HBV genotypes [45,46].
Standardization of “in house”-HDV-RNA assays is import-
ant to allow comparisons of results among studies. The
HDV genotype 3 sequences generated in this study and
deposited in a public gene bank contribute to the some-
what limited number of HDV sequences available from
this endemic region. Although a significant number of
individuals participated in this study, we acknowledge that
our sample size may not be representative of the vast
geographic territory of the western Amazon. However,
molecular studies from this region need to take into
account limitations and logistic difficulties to reach and
screen inhabitants of remote, small municipalities disper-
sed into the jungle, such as the screening performed in
Eirunepe city.
Conclusion
The description of HBV and HDV genotypes circulating
in the western Amazon is important to reveal both their
pattern of endemicity and their relevance on the regional
epidemics. The Amazon is a highly endemic region for
these infections and their control is challenged by its
vast territorial dimension, with small, hard-to-reach mu-
nicipalities dispersed into the jungle, and by the diverse
ethnic composition of those affected. Surveillance of HBV
and HDV genotypes in the western Amazon region, to-
gether with universal HBV vaccination, better educa-
tional programs about these viruses including their
modes of transmission and improvements in socioeco-
nomic conditions in these remote areas remain the
cornerstone for better control strategies.
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